Geron

$1.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Geron

Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.

Stock Analysis

last close $1.47
1-mo return -2.6%
3-mo return 8.9%
avg daily vol. 2M
52-week high 2.36
52-week low 1.2
market cap. $473M
forward pe -
annual div. -
roe -56.1%
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 41.9%
baraka

Subscribe now for daily local and international financial news

Subscribe